Electrophysiologic Studies EPS

Imaging studies

Electromyography and nerve conduction velocity studies

Clinical Trials Phase News

Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will norma...

p38 mitogen activated protein kinase MAPK Inhibitors

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation o...

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease

US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive new data from two Phase III studies - ENGAGE and ENCORE - of eliglustat tartrate, its investigat...

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigat...

Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in p...

Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for ...

Validus Pharmaceuticals agrees to purchase six well known product lines from Novartis

Validus Pharmaceuticals together with Wood Creek Capital Management, announced the acquisition of the U.S. rights to six well-known product lines from Novartis Pharmaceuticals Corporation: Lopressor (...

Oral Drug for Gaucher Disease Promising

Sanofi said its experimental oral drug for Gaucher disease, eliglustat tartrate, met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory...

Eliglustat tartrate: Phase III data

Assessments of thermal antinociceptive effects of butorphanol and human observer effect on quantitative evaluation of analgesia in green iguanas (Iguana iguana).

Objective-To determine whether butorphanol induces thermal antinociception in green iguanas (Iguana iguana) and assess the human observer effect on quantitative evaluation of butorphanol-induced analg...

Compatibility of butorphanol and droperidol in 0.9% sodium chloride injection.

The compatibility and stability of butorphanol tartrate and droperidol in polyvinyl chloride (PVC) bags and glass bottles stored at 4°C and 25°C for up to 15 days were studied.

Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate.

Objective  To determine the pharmacokinetics and pharmacodynamics of the neurosteroid anaesthetic, alfaxalone, in neonatal foals after a single intravenous (IV) injection of alfaxalone following pre...

Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study.

PURPOSE: Pruritus associated with intrathecal opioid administration is a common side effect. There is evidence that κ-opioid receptor agonists have antipruritic activity. Butorphanol has agonist acti...

2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.

TNF-α converting enzyme (TACE) inhibitors are promising agents to treat inflammatory disorders and cancer. We have investigated novel tartrate diamide TACE inhibitors where the tartrate core binds to...